Stay updated with breaking news from Accelerated Approval Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine
Alzheimer’s Disease is a progressive type of dementia with no cure. The FDA has approved 5 drugs for treating symptoms and one that may slow cognitive decline.
Share this article Share this article NEW ORLEANS, May 7, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Tricida, Inc. (NasdaqGS: TCDA). On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Company's New Drug Application (NDA) for its drug candidate, veverimer (TRC101) wherein "the FDA has identified deficiencies that preclude discu...
Posted on 532 Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Tricida, Inc. (NasdaqGS: TCDA). On July 15, 2020, the Company disclosed that it received a notification from the U.S. Food and Drug Administration (FDA) regarding its ongoing review of the Company’s New Drug Application (NDA) for its drug candidate, veverimer (TRC101) wherein “the FDA has identified deficiencies that preclude discu...
Share this article Share this article NEW YORK, March 8, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Tricida Inc. ("Tricida" or the "Company") (NASDAQ: TCDA) from September 4, 2019 through October 28, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the Northern District of California alleges violations of the Securities Exch...